{"id":37463,"date":"2020-08-16T10:07:07","date_gmt":"2020-08-16T10:07:07","guid":{"rendered":"https:\/\/www.healthbenefitstimes.com\/glossary\/?p=37463"},"modified":"2020-08-16T10:07:07","modified_gmt":"2020-08-16T10:07:07","slug":"committee-for-proprietary-medicinal-products-cpmp","status":"publish","type":"post","link":"https:\/\/www.healthbenefitstimes.com\/glossary\/committee-for-proprietary-medicinal-products-cpmp\/","title":{"rendered":"Committee for proprietary medicinal products (CPMP)"},"content":{"rendered":"

The European Union’s (EU’s) scientific advisory organization dealing with new human pharmaceuticals approval. Its recommendations (e.g., to either approve or not approve a new product) are usually adopted by the European Medicines Evaluation Agency (EMEA), to which the CPMP reports.<\/p>\n

\n

Within 60 days of a CPMP “approval for recommendation” being adopted by the EMEA, each of the EU’s member countries must advise the EMEA of its progress toward a regulatory decision on that pharmaceutical’s submission for approvals.<\/p>\n

\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

The European Union’s (EU’s) scientific advisory organization dealing with new human pharmaceuticals approval. Its recommendations (e.g., to either approve or not approve a new product) are usually adopted by the European Medicines Evaluation Agency (EMEA), to which the CPMP reports. Within 60 days of a CPMP “approval for recommendation” being adopted by the EMEA, each […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-37463","post","type-post","status-publish","format-standard","hentry","category-c"],"yoast_head":"\nCommittee for proprietary medicinal products (CPMP) - Definition of Committee for proprietary medicinal products (CPMP)<\/title>\n<meta name=\"description\" content=\"The European Union's (EU's) scientific advisory organization dealing with new human pharmaceuticals approval. Its recommendations (e.g., to either approve or not approve a new product) are usually adopted by the European Medicines Evaluation Agency (EMEA), to which the CPMP reports.Within 60 days of a CPMP "approval for recommendation" being adopted by the EMEA, each of the EU's member countries must advise the EMEA of its progress toward a regulatory decision on that pharmaceutical's submission for approvals.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.healthbenefitstimes.com\/glossary\/committee-for-proprietary-medicinal-products-cpmp\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Committee for proprietary medicinal products (CPMP) - Definition of Committee for proprietary medicinal products (CPMP)\" \/>\n<meta property=\"og:description\" content=\"The European Union's (EU's) scientific advisory organization dealing with new human pharmaceuticals approval. Its recommendations (e.g., to either approve or not approve a new product) are usually adopted by the European Medicines Evaluation Agency (EMEA), to which the CPMP reports.Within 60 days of a CPMP "approval for recommendation" being adopted by the EMEA, each of the EU's member countries must advise the EMEA of its progress toward a regulatory decision on that pharmaceutical's submission for approvals.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.healthbenefitstimes.com\/glossary\/committee-for-proprietary-medicinal-products-cpmp\/\" \/>\n<meta property=\"og:site_name\" content=\"Glossary\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-16T10:07:07+00:00\" \/>\n<meta name=\"author\" content=\"Glossary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Glossary\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/committee-for-proprietary-medicinal-products-cpmp\/\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/committee-for-proprietary-medicinal-products-cpmp\/\",\"name\":\"Committee for proprietary medicinal products (CPMP) - Definition of Committee for proprietary medicinal products (CPMP)\",\"isPartOf\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\"},\"datePublished\":\"2020-08-16T10:07:07+00:00\",\"dateModified\":\"2020-08-16T10:07:07+00:00\",\"author\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\"},\"description\":\"The European Union's (EU's) scientific advisory organization dealing with new human pharmaceuticals approval. Its recommendations (e.g., to either approve or not approve a new product) are usually adopted by the European Medicines Evaluation Agency (EMEA), to which the CPMP reports.Within 60 days of a CPMP \\\"approval for recommendation\\\" being adopted by the EMEA, each of the EU's member countries must advise the EMEA of its progress toward a regulatory decision on that pharmaceutical's submission for approvals.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/committee-for-proprietary-medicinal-products-cpmp\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.healthbenefitstimes.com\/glossary\/committee-for-proprietary-medicinal-products-cpmp\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/committee-for-proprietary-medicinal-products-cpmp\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Committee for proprietary medicinal products (CPMP)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\",\"name\":\"Glossary\",\"description\":\"Difinitions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\",\"name\":\"Glossary\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Committee for proprietary medicinal products (CPMP) - Definition of Committee for proprietary medicinal products (CPMP)","description":"The European Union's (EU's) scientific advisory organization dealing with new human pharmaceuticals approval. Its recommendations (e.g., to either approve or not approve a new product) are usually adopted by the European Medicines Evaluation Agency (EMEA), to which the CPMP reports.Within 60 days of a CPMP \"approval for recommendation\" being adopted by the EMEA, each of the EU's member countries must advise the EMEA of its progress toward a regulatory decision on that pharmaceutical's submission for approvals.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.healthbenefitstimes.com\/glossary\/committee-for-proprietary-medicinal-products-cpmp\/","og_locale":"en_US","og_type":"article","og_title":"Committee for proprietary medicinal products (CPMP) - Definition of Committee for proprietary medicinal products (CPMP)","og_description":"The European Union's (EU's) scientific advisory organization dealing with new human pharmaceuticals approval. Its recommendations (e.g., to either approve or not approve a new product) are usually adopted by the European Medicines Evaluation Agency (EMEA), to which the CPMP reports.Within 60 days of a CPMP \"approval for recommendation\" being adopted by the EMEA, each of the EU's member countries must advise the EMEA of its progress toward a regulatory decision on that pharmaceutical's submission for approvals.","og_url":"https:\/\/www.healthbenefitstimes.com\/glossary\/committee-for-proprietary-medicinal-products-cpmp\/","og_site_name":"Glossary","article_published_time":"2020-08-16T10:07:07+00:00","author":"Glossary","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Glossary"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/committee-for-proprietary-medicinal-products-cpmp\/","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/committee-for-proprietary-medicinal-products-cpmp\/","name":"Committee for proprietary medicinal products (CPMP) - Definition of Committee for proprietary medicinal products (CPMP)","isPartOf":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website"},"datePublished":"2020-08-16T10:07:07+00:00","dateModified":"2020-08-16T10:07:07+00:00","author":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5"},"description":"The European Union's (EU's) scientific advisory organization dealing with new human pharmaceuticals approval. Its recommendations (e.g., to either approve or not approve a new product) are usually adopted by the European Medicines Evaluation Agency (EMEA), to which the CPMP reports.Within 60 days of a CPMP \"approval for recommendation\" being adopted by the EMEA, each of the EU's member countries must advise the EMEA of its progress toward a regulatory decision on that pharmaceutical's submission for approvals.","breadcrumb":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/committee-for-proprietary-medicinal-products-cpmp\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.healthbenefitstimes.com\/glossary\/committee-for-proprietary-medicinal-products-cpmp\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/committee-for-proprietary-medicinal-products-cpmp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.healthbenefitstimes.com\/glossary\/"},{"@type":"ListItem","position":2,"name":"Committee for proprietary medicinal products (CPMP)"}]},{"@type":"WebSite","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/","name":"Glossary","description":"Difinitions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5","name":"Glossary","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/"}]}},"_links":{"self":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/37463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/comments?post=37463"}],"version-history":[{"count":1,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/37463\/revisions"}],"predecessor-version":[{"id":37464,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/37463\/revisions\/37464"}],"wp:attachment":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/media?parent=37463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/categories?post=37463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/tags?post=37463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}